

1 **CHOmpact: a reduced metabolic model of Chinese hamster ovary cells**
2 **with enhanced interpretability**

3 Ioscani Jiménez del Val^{1,*}, Sarantos Kyriakopoulos^{2,‡}, Simone Albrecht³, Henning Stockmann³,
4 Pauline M Rudd^{3,†}, Karen M Polizzi⁴ and Cleo Kontoravdi⁴

5 ¹ School of Chemical & Bioprocess Engineering, University College Dublin D04 V1W8, Ireland

6 ² MS&T, BioMarin Manufacturing Ireland, Cork P43 R298, Ireland

7 ³ NIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Dublin
8 A94 X099, Ireland

9 ⁴ Department of Chemical Engineering, Imperial College London SW7 2AZ, United Kingdom

10 *Author to whom correspondence should be addressed.

11 e-mail: ioscani.jimenezdelval@ucd.ie

12

13 † Present address: Bioprocessing Technology Institute, Agency for Science, Technology and
14 Research (A*STAR) 138668, Singapore

15 ‡ Present address: Process Development, Lonza Group AG, Wisp 3930, Switzerland

16

17

18 **Abstract**

19 Metabolic modelling has emerged as a key tool for the characterisation of biopharmaceutical cell
20 culture processes. Metabolic models have also been instrumental in identifying genetic
21 engineering targets and developing feeding strategies that optimise the growth and productivity
22 of Chinese hamster ovary (CHO) cells. Despite their success, metabolic models of CHO cells still
23 present considerable challenges. Genome scale metabolic models (GeMs) of CHO cells are very
24 large (>6000 reactions) and are, therefore, difficult to constrain to yield physiologically
25 consistent flux distributions. The large scale of GeMs also makes interpretation of their outputs
26 difficult. To address these challenges, we have developed CHOmpact, a reduced metabolic
27 network that encompasses 101 metabolites linked through 144 reactions. Our compact reaction
28 network allows us to deploy multi-objective optimisation and ensure that the computed flux
29 distributions are physiologically consistent. Furthermore, our CHOmpact model delivers
30 enhanced interpretability of simulation results and has allowed us to identify the mechanisms
31 governing shifts in the anaplerotic consumption of asparagine and glutamate as well as an
32 important mechanism of ammonia detoxification within mitochondria. CHOmpact, thus,
33 addresses key challenges of large-scale metabolic models and, with further development, will
34 serve as a platform to develop dynamic metabolic models for the control and optimisation of
35 biopharmaceutical cell culture processes.

36 **1. Introduction**

37 Production of recombinant proteins is known to compete with biomass synthesis for externally
38 provided nutrients. This is particularly true for mammalian cell lines, such as Chinese hamster
39 ovary (CHO) cells, which are the dominant host for industrial production of therapeutic proteins
40 (O'Flaherty et al., 2020). Metabolic modelling has become an essential tool for understanding
41 resource allocation and, coupled with advances in genome editing, designing rational cell
42 engineering strategies. Publication of the CHO-K1 genome, and the omics analyses this enabled,
43 laid the foundation for systems-level understanding of this host. This knowledge has been
44 reconstructed mathematically in a community-curated genome-scale metabolic model (GeM) of

45 the CHO cell termed iCHO1766 (Hefzi et al., 2016). Crucially, the GeM organised knowledge of all
46 biochemical conversions, transport and exchange reactions to create a large, interlinked network
47 of metabolites and their associated reactions.

48 The inclusion of gene-protein reaction associations provided a direct link between genes and
49 metabolic reactions. Since then, significant expansions and improvements to iCHO1766 have
50 been achieved, such as gap-filling studies that also removed dead-end reactions (Fouladiha et al.,
51 2021), and the integration of a core protein secretory pathway, iCHO2048, enabling the
52 computation of energetic costs and machinery demands of each secreted protein (Gutierrez et al.,
53 2020). Interestingly, iCHO2048 was subsequently used to direct host cell protein knockout
54 studies which resulted in increased recombinant protein productivity and a cleaner feedstock for
55 downstream processing steps (Kol et al., 2020), highlighting the power these models hold for
56 identifying diverse cellular engineering strategies.

57 The solution of GeMs, and any undetermined metabolic model, relies on constraint-based
58 methods, such as flux balance analysis (FBA), to predict steady-state intracellular flux
59 distributions (Orth et al., 2010). Although FBA offers the advantage of not requiring detailed
60 knowledge of enzymatic kinetic parameters, it does not return a unique set of intracellular flux
61 values. In addition, the larger the metabolic network considered, the more difficult it becomes to
62 interpret such predictions (Gardner and Boyle, 2017). GeMs therefore require large datasets,
63 preferably across different omics levels (e.g., metabolomic, transcriptomic) to increase
64 confidence in results. This is also true for curating GeMs for specific cell lines or systems, raising
65 the need for extensive experimentation that goes beyond typical analytical measurements
66 conducted in an industrial setting.

67 Several algorithms have been developed to improve the predictive performance of GeMs, for
68 example by constraining the amount of carbon able to flowthrough reaction fluxes, based on the
69 maximum amount carbon uptake by the cell (ccFBA) (Lularevic et al., 2019), taking into account
70 the selective pressure that exists within cell cultures for fast-growing cell lines with a low enzyme

71 usage (Lewis et al., 2010), or introducing enzyme capacity constraints (Yeo et al., 2020). Despite
72 these advances, both the accuracy and interpretability of intracellular flux predictions remain
73 challenging. An additional limitation is the computational difficulty in creating dynamic versions
74 of GeMs that would reflect the nature of cell culture processes, although recent efforts coupling a
75 CHO GeM with statistical models have yielded promising results in predicting the time evolution
76 of extracellular amino acid concentrations (Martínez et al., 2015).

77 In this work, we introduce a reduced-scale metabolic model, CHOmpact, where the reaction
78 network is based on the work by Carinhas et al. (2013) and has been augmented with a detailed
79 description the aspartate-malate (Asp-Mal) shuttle, the urea cycle, de novo serine synthesis from
80 glycolytic intermediates, and nucleotide sugar donor biosynthesis. The resulting network
81 comprises 101 metabolites and 144 reactions, which due to its compact nature, significantly
82 enhances the interpretability of simulation results. The reduced scale of the network and
83 associated FBA problem also allow for more complex, non-linear formulations of the objective
84 function to be incorporated compared to biomass maximisation that is often employed in FBA of
85 GeMs. The multi-objective optimisation framework used to solve CHOmpact allows us to solve
86 across all phases of cell culture and provides insight into the dynamics of cellular metabolism. We
87 envisage that the advantages presented by CHOmpact will enable the development of dynamic
88 flux balance models that can serve as digital twins for the control and optimisation of
89 biopharmaceutical cell culture processes.

90 **2. Materials & Methods**

91 **2.1. Experimental**

92 **2.1.1. Cell culture**

93 The GS46 GS-CHO cell line producing a humanized anti-Tumour-Associated Glycoprotein (TAG-
94 72) IgG4 κ mAb (cB72.3), a kind gift by Lonza Biologics (Slough, UK), was cultured with three
95 different amino acid feeds: Feed C, Feed U and Feed U40 (Kyriakopoulos and Kontoravdi, 2014).
96 Briefly, triplicate cultures for each feeding regime were performed in orbitally shaken (140 rpm)

97 250mL vented conical flasks (Corning, Amsterdam, Netherlands) with a 50mL working volume.
98 The cultures were performed in a humidified incubator with CO₂ controlled at 8% and
99 temperature set at 36.5°C. The basal culture medium for all cultures was CD CHO (Life
100 Technologies, Paisley, UK) supplemented with 25µM methionine sulfoximine (Sigma-Aldrich,
101 Dorset, UK). All feeding regimes consisted in adding 10% v/v every 48 hours of culture starting
102 on day 2. The Feed C regime used commercial CD EfficientFeed™ C AGT™ (Invitrogen, UK),
103 whereas the U and U40 feeds aimed to provide growth-limiting nutrients (glucose and amino
104 acids) beyond the amounts available in Feed C. The glucose and amino acid concentrations
105 present in the different feeds is detailed in previous work by Kyriakopoulos and Kontoravdi
106 (2014).

107 **2.1.2. Analytical methods**

108 Viable and dead cell density was determined using the trypan blue dye exclusion method and
109 light microscopy. mAb titre was determined using the BLitz® system (Pall ForteBio, Portsmouth,
110 UK). Time profiles for glucose, lactate, and ammonia were generated using the Bioprofile 400
111 analyser (NOVA Biomedical, Waltham, MA). Residual amino acid profiles were generated using
112 the PicoTag method (Waters, Hertfordshire, UK) on an Alliance HPLC instrument (Waters,
113 Hertfordshire, UK). Extracellular pyruvate concentrations were determined with an enzyme
114 assay kit (Abcam, Cambridge, UK). mAb Fc glycoprofiling was performed with an automated
115 sample preparation workflow (Stockmann et al., 2013). Briefly, the mAb samples were affinity-
116 purified from the cell culture supernatant with a 96-well Protein G IgG purification plate (Thermo
117 Fisher Scientific, Dublin, Ireland). Glycans were released from the mAb through PNGase
118 (Prozyme, Hayward, California) digestion and labelled with 2-amino benzamide (Ludger, Oxford,
119 UK). Labelled glycans were separated using ultra-performance hydrophilic interaction
120 chromatography (UPLC-HILIC) and quantified through fluorescence detection (Stockmann et al.,
121 2013). Glycans were initially assigned by comparing their Glucose Unit retention times with those
122 available in the NIBRT GlycoBase 3.2 structural N-glycan library (Campbell et al., 2008). Glycan

123 assignment was confirmed through weak anion exchange chromatography and quadrupole time-
124 of-flight mass spectrometry on exoglycosidase-digested samples (Albrecht et al., 2014).

125 **2.1.3. Dry cell weight measurement**

126 Cells were cultured under the same conditions as described for Feed C, above. Duplicate cultures
127 were harvested at day 4 and day 10 for dry cell weight (DCW) measurements for cells undergoing
128 mid-exponential and stationary growth, respectively. Prior to harvest, viable cell density was
129 determined using the trypan blue dye exclusion method. Immediately after cell counting, 40mL
130 of the cultures was harvested and centrifuged at 1000g for one minute in pre-weighed 50mL
131 falcon tubes. The supernatant was then discarded, and the cell pellets were washed once with
132 40mL 0.9% w/v NaCl (Sigma-Aldrich, Dorset, UK) solution and centrifuged at 1000g for one
133 minute. The wash was discarded, and the cell pellet was left to dry in a non-humidified incubator
134 at 37°C until no changes in weight were observed. The tubes were weighed within 1mg accuracy
135 (ACCULAB, Sartorius, Surrey, UK).

136 **2.1.4. Data processing and analysis**

137 The cell-specific rates for nutrient consumption and metabolite/product secretion, $q_i(t_n)$, were
138 calculated by performing linear regressions to obtain the slopes in Eq. 1 (Sauer et al., 2000),
139 where $N_{i,cons}(t_n)$ is the consumed/produced amount of component i (in units of $nmol_i$ or mg_{mAb})
140 up to time t_n and $IVC(t_n)$ is the integral of viable cells up to time t_n in units of 10^6 cells h.

$$N_{i,cons}(t_n) = q_i(t_n)IVC(t_n) \quad \text{Eq. 1}$$

$$N_{i,cons}(t_n) = [C]_{i,res}(t_n)Vol(t_n) - \sum_{j=1}^n [C]_{i,feed}Vol_{feed}(t_j) \quad \text{Eq. 2}$$

$$IVC(t_n) = \sum_{j=1}^n \frac{[X_v](t_j)Vol(t_j) + [X_v](t_{j-1})Vol(t_{j-1})}{2} (t_j - t_{j-1}) \quad \text{Eq. 3}$$

141 $N_{i,cons}(t_n)$ and $IVC(t_n)$ were computed using Eq. 2 and Eq. 3, respectively. In Eq. 2, $[C]_{i,res}(t_n)$ is
142 the residual concentration of component i at time t_n , $[C]_{i,feed}$ is the concentration of component

143 i in the feed and $Vol_{fed}(t_j)$ is the feed volume added at time j . In Eq. 3, $[X_v](t_j)$ is cell density at
144 time t_j and $Vol(t_j)$ is liquid volume in the culture flask at time t_j .

145 The linear regressions for the determination of cell specific uptake rates were computed using
146 the LINEST function in Microsoft Excel. Confidence intervals for the obtained $q_i(t_n)$ values were
147 computed with the least square residuals and a t-value for $p = 0.05$. Data analysis identified six
148 distinct intervals with constant uptake/secretion rates: early exponential, mid-exponential, late
149 exponential, early stationary, and stationary. Raw cell culture data is presented in Supplementary
150 Figure 1, and the processed data, along with the identified intervals are presented in
151 Supplementary Figure 2.

152 The amount of mAb glycoform secreted across different intervals was calculated using Eq. 4,
153 where f_k represents the fraction of mAb glycoform k secreted during the time interval
154 $(t_n - t_{n-1})$, $[mAb]_i(t_n)$ is the concentration of mAb glycoform k present at time t_n and $[mAb](t_n)$
155 is the total mAb titre at time t_n (del Val et al., 2016a; Fan et al., 2015).

$$f_k = \frac{[mAb]_k(t_n) - [mAb]_k(t_{n-1})}{[mAb](t_n) - [mAb](t_{n-1})} \quad \text{Eq. 4}$$

156 **2.2. Flux balance model development**

157 Our flux balance model (Figure 1) is based on previous work for GS-CHO cells (Carinhas et al.,
158 2013), which has been expanded to include the aspartate-malate (Asp-Mal) shuttle (Mulukutla et
159 al., 2012; Nolan and Lee, 2011), the urea cycle (Zamorano et al., 2010), *de novo* serine synthesis
160 from glycolytic intermediates, and ATP synthesis via oxidative phosphorylation. The pathway for
161 nucleotide sugar donor biosynthesis (Kremkow and Lee, 2018) has also been included.

162 Manual curation of our FBA model was performed using the KEGG database (Kanehisa et al., 2017;
163 Kanehisa et al., 2019) and the reference CHO-K1 and *Cricetulus griseus* genome annotations
164 (Kremkow et al., 2015; Lewis et al., 2013; Rupp et al., 2018). The resulting model comprises 101
165 metabolites linked through 299 reactions (Supplementary Table 1). Supplementary Table 1 also

166 provides links for all enzymatic reactions to KEGG (Kanehisa et al., 2017; Kanehisa et al., 2019)
 167 as well as to reference sequences in the NCBI database (O'Leary et al., 2016).




Figure 1. FBA reaction network

168
 169
 170 The present FBA model considers 101 species linked through 144 fluxes. Different colours indicate
 171 particular metabolic pathways: glycolysis, TCA and oxidative phosphorylation (Green), nucleotide
 172 sugar donor metabolism (Red), aspartate-malate shuttle (Orange), urea cycle (Purple), amino acid
 173 and nucleotide metabolism (Dark Blue) and cycle fluxes that must be constrained and/or estimated
 174 during optimisation (Light Blue).

175 Sequential reactions throughout the metabolic pathways were combined into single reaction
 176 fluxes to reduce degrees of freedom within the model (Nolan and Lee, 2011). Overall, the resulting
 177 metabolic model considers material balances for 101 species, one additional equation that
 178 defines the consumption of ATP towards active amino acid transport and 144 fluxes (Figure 1

179 and Supplementary File, Section 2), yielding 42 degrees of freedom. The full stoichiometric matrix
180 underlying our model is presented in Supplementary Table 2.

181 **2.2.1. Stoichiometric equations for biomass and product**

182 Calculations for the biomass stoichiometric coefficients are presented in Supplementary Table 3.
183 Based on experimental measurements, the biomass stoichiometric equation considers a dry cell
184 weight of 219 pg/cell for exponentially growing cells and 311 pg/cell for cells in stationary phase.
185 The mass composition of GS-CHO cells is based on Sheikh et al. (2005) and Hefzi et al. (2016) and
186 assumes 74.2% protein, 11.1% lipids, 5.0% RNA, 1.4% DNA, 0.4% glycogen, 0.2% N-glycans, 0.3%
187 O-glycans, 2.9% other intracellular components (e.g. MTHF, NAD(P)H, AcCoA) and 4.5% non-
188 balanced components (ash).

189 The individual amino acid content of protein was computed from CHO cell proteomic data
190 (Baycin-Hizal et al., 2012), as reported previously (del Val et al., 2016b). The glycan content of
191 biomass, which has been included by using the biomass NSD stoichiometric coefficients for
192 cellular protein N- and O-linked glycosylation as well as glycolipid glycosylation (del Val et al.,
193 2016b).

194 The stoichiometric equation for the cB72.3 product, a humanised IgG4 κ mAb, was computed
195 based on the amino acid sequences for the human IgG4 Fc (Heilig et al., 2003), the constant
196 fragment of a human kappa light chain (Brady et al., 1991; Xiang et al., 1999), as well as the
197 variable heavy and light chain fragments for the cB72.3 mAb (Xiang et al., 1999). The sequences
198 and calculations for the mAb amino acid stoichiometric coefficients are presented in
199 Supplementary Table 4.

200 mAb glycoprofiling at three culture timepoints (192h, 240h, and 288h) allowed us to calculate
201 stoichiometric coefficients for NSD consumption towards mAb glycosylation across three culture
202 intervals: 0 to 192 hours, 192 to 240 hours, and 240 to 288 hours. These calculations were made
203 with Eq. 4, and the obtained stoichiometric values are presented in Supplementary Table 5.

204 **2.2.2. FBA solution: multi-objective optimisation**

205 As with most FBA models, no intracellular accumulation of species has been assumed in the
206 material balances generated from our stoichiometric matrix, leading to a problem of the form:

$$S \times F = 0 \quad \text{Eq. 5}$$

207 Where S is the stoichiometric matrix defined in Supplementary Table 2 and F is the vector of
208 unknown fluxes. Because the model contains more unknown fluxes (144) than equations (102),
209 it must be solved using constraint-based optimisation strategies that have been outlined
210 elsewhere (Banga, 2008).

211 Two constraint-based optimisation strategies have been used to solve our FBA. The first is typical
212 in that it maximises the rate of biomass synthesis while maintaining the transport flux for all
213 nutrients, metabolites, and product set to their experimentally determined values. Reaction
214 reversibility constraints, based on enzyme data available in the KEGG (Kanehisa et al., 2017;
215 Kanehisa et al., 2019) and BRENDA (Jeske et al., 2019) databases, were included and are indicated
216 in Supplementary Tables 1 and 2.

217 The multi-objective optimisation strategy proposed herein simultaneously maximises the fluxes
218 where ATP is synthesised while minimising the sum of squared intracellular fluxes. This objective
219 function represents maximum energetic efficiency by the cells (Schuetz et al., 2007) and was used
220 to ensure consistent directionality of central carbon metabolism fluxes. Alongside maximising the
221 energetic efficiency of the cells, the squared difference between measured and computed fluxes
222 was minimised to ensure consistency between our flux model results and our experimental
223 measurements. In order to avoid flux F_{15} being bypassed by F_{17} , the F_{17}/F_{14} ratio was constrained
224 to values within the $[0, 1]$ interval and minimised. Finally, the sum of non-measured by-product
225 secretion fluxes was also minimised as part of this multi-objective optimisation strategy. As with
226 the traditional optimisation strategy, flux reversibility constraints were included within our
227 multi-objective optimisation strategy.

228 An additional constraint was included for the maximum allowable fluxes along the aspartate-
229 malate (Asp-Mal) shuttle. Flux through the Asp-Mal shuttle was constrained by limiting the
230 maximum amount of glutamate transported into the mitochondrial lumen (F_{20}) to the flux of
231 glutamate internalised by the cells or produced through reactions independent of the Asp-Mal
232 shuttle. F_{20} was constrained because this antiport transport flux is the rate-limiting step of the
233 Asp-Mal shuttle (LaNoue et al., 1974; LaNoue and Tischler, 1974).

234 Importantly, a constraint for Asp-Mal fluxes is required because the sum of all reactions in the
235 shuttle result, exclusively, in net transport of cytosolic NADH into the mitochondrial lumen (see
236 Supplementary File). Thus, the fluxes through the reactions underlying the Asp-Mal shuttle can
237 take any value as long as the balances for cytosolic and mitochondrial NADH are met (i.e., all other
238 fluxes cancel each other out). This is likely to be the cause of what may be considered high (and
239 possibly inconsistent) Asp-Mal shuttle fluxes with values that are comparable with glucose
240 uptake fluxes (Mulukutla et al., 2012; Nolan and Lee, 2011). Avoiding these potential
241 inconsistencies led us to include this Asp-Mal constraint within our FBA solution strategy.

242 Our multi-objective optimisation strategy also constrains F_{16} to be 1% of the glucose uptake flux
243 (F_{105}), as previously determined for CHO cells undergoing both exponential and stationary
244 growth (Ahn and Antoniewicz, 2013). Both optimisation strategies are outlined in Table 1, where
245 F_j are all intracellular fluxes, $ATP_{synth.}$ is the squared sum of ATP synthesis reaction fluxes, SSE
246 is the sum of square errors between the measured and computed transport fluxes, $F_{k,BP}$ are the
247 fluxes of by-product synthesis reactions, LB_i and UB_i are lower and upper bounds for flux values
248 (a reaction is irreversible when $LB_i = 0$), $C_{Asp/Mal}$ is the Asp-Mal shuttle constraint, ε represents
249 a small threshold value, $F_m^{Comp.}$ and $F_m^{Meas.}$ are the computed and measured transport fluxes,
250 respectively, F_g are the fluxes of reactions where Glu is produced or consumed (excluding Asp-
251 Mal shuttle reactions), and v_g is the stoichiometric coefficient for these Glu synthesis reactions.

252 **Table 1. Optimisation strategies for flux balance model solution**

BM maximisation	Multi-objective optimisation
$\begin{aligned} & \text{MAX}(F_{142}) \\ & \text{Subject to:} \\ & \left\{ \begin{array}{l} LB_i \leq F_i \leq UB_i \\ \left[100 \left(\frac{F_{143}}{q_p} - 1 \right) \right]^2 \leq \varepsilon_p \end{array} \right. \end{aligned}$	$\begin{aligned} & \text{MIN} \left(\frac{\sum_{j=1}^{104} F_j^2}{ATP_{synth.}} + SSE + \sum_{k=1}^{14} F_{k,BP}^2 + \frac{F_{17}}{F_{14}} \right) \\ & \text{Subject to:} \\ & \left\{ \begin{array}{l} LB_i \leq F_i \leq UB_i \\ 0 \leq \frac{F_{17}}{F_{14}} \leq 1 \\ C_{Asp/Mal} \leq \varepsilon_{Asp/Mal} \\ \left[100 \left(\frac{F_{16}}{F_{105}} - 0.01 \right) \right]^2 \leq \varepsilon_{16/105} \end{array} \right. \\ & \text{Where:} \\ & ATP_{synth.} = (F_5)^2 + (F_6)^2 + (1.5F_{18})^2 + (2.5F_{19})^2 \\ & SSE = \sum_{k=1}^{38} \left[100 \left(\frac{F_m^{Comp.}}{F_m^{Meas.}} - 1 \right) \right]^2 \\ & C_{Asp/Mal} = \left(\sum_g^{18} v_g F_g - F_{20} \right)^2 \end{aligned}$

253


254 The biomass maximisation strategy was used to compare performance of our reduced FBA model
 255 with the iCHO1766 GeM (Hefzi et al., 2016) while the energetic efficiency maximisation strategy
 256 was used for all other simulations presented herein. All optimisations were performed using the
 257 nonlinear programming sequential quadratic programming (NLPSQP) solver built into gPROMS
 258 ModelBuilder v6.0.2 (Process Systems Enterprise) on a standard desktop workstation (AMD
 259 Ryzen 2700x @ 4GHz and 16GB RAM).

260 3. Results and discussion

261 3.1. The reduced reaction network performs comparably with the iCHO1766 GeM

262 The maximum specific growth rates ($\mu_{g,max}$) of multiple CHO cell lines cultured under different
 263 conditions were calculated through the biomass synthesis rate maximisation strategy. The

264 required inputs for this solution strategy, namely the nutrient, metabolite, and product transport
265 fluxes, were obtained from previously published data (Carinhas et al., 2013; Martínez et al., 2015;
266 Selvarasu et al., 2012), as summarized in the supplementary information of Hefzi et al. (2016).
267 In order to assess whether our assumed biomass composition and reduced reaction network
268 performs comparably with a large-scale model for CHO cell metabolism, Figure 2 compares our
269 predicted $\mu_{g,max}$ values with those obtained using the iCHO1766 GeM (Hefzi et al., 2016) and the
270 corresponding experimental data.



271
272 **Figure 2. Comparison of experimentally determined and predicted maximum specific growth rates**
273 **($\mu_{g,max}$) for different CHO cell lines and culture conditions. The dark blue bars present the**
274 **experimentally determined $\mu_{g,max}$ values reported by Carinhas et al. (2013), Martínez et al. (2015),**
275 **and Selvarasu et al. (2012). The medium blue bars present $\mu_{g,max}$ predictions reported by Hefzi et**
276 **al. (2016) and the light blue bars show the $\mu_{g,max}$ values predicted with CHOmpact.**

277 Figure 2 shows that our model accurately predicts (within 15% deviation) the experimental data
278 for the Low Producing CHO cell line cultured with sodium butyrate (LP+NaBu) from Carinhas et
279 al. (2013) as well as the early and late exponential growth phases reported by Selvarasu et al.
280 (2012). Our model underpredicts the growth rate reported for the High Producing CHO cell line

281 cultured in absence and presence of NaBu (HP and HP+NaBu, respectively) (Carinhas et al., 2013)
282 as well as CHO cells cultured under normal and mild hypothermic conditions (Warm 1, Warm 2,
283 and Cold 1, respectively) (Martínez et al., 2015). Our model overpredicts the biomass synthesis
284 rate of the second hypothermic dataset (Cold 2) reported by Martínez et al. (2015).

285 $\mu_{g,max}$ optimisations were performed using the biomass composition assumed by Hefzi et al.
286 (2016) in order to discern whether the deviation in predictive capabilities of our model were
287 caused by our assumed biomass composition. These optimisations yield overall average
288 deviations from the experimental data that are indistinguishable from those obtained with our
289 assumed biomass composition (data not shown). These results are expected, especially when
290 considering that the minor differences between our assumed biomass composition and the one
291 used in the GEM involve prototrophic amino acids (Ala, Gln, Gly) (Supplementary Figure 4).

292 Although the deviations are considerable in some cases, our predictions are similar to those
293 reported for the CHO GeM (Hefzi et al., 2016), and are better for Carinhas HP, Selvarasu Late Exp,
294 Martinez Cold 1, and Martinez Warm 2. Overall, the GeM has an average percent deviation across
295 the ten experimental $\mu_{g,max}$ values of 30%, whereas our model has an average deviation of 32.5%.
296 When considering that our model includes only 144 reactions when compared to 6,663 in the
297 GeM, a 2.5% reduction in predictive capability is acceptable, especially considering gains in model
298 output consistency and interpretability (to be discussed in subsequent sections) as well as
299 reductions in computational expense, when using non-linear, multi-objective optimisation
300 strategies for solution.

301 **3.1.1. CHOmpact identifies the source of μ_g prediction inaccuracies**

302 An advantage of our proposed multi-objective optimisation strategy is that it enables the
303 identification of nutrient uptake rates that lead to shortfalls in calculated specific growth rates
304 when compared with the experimental values. This is achieved by constraining the maximum
305 allowable value for the percent error of biomass growth rate and specific productivity to low
306 values (5×10^{-6}) while fixing the uptake/secretion flux values of Glc, Lac, NH_4^+ , Pyr, Ala, Asn, Asp,

307 Glu, Gly to the experimentally determined flux values. The upper bounds for the uptake fluxes of
 308 the remaining (mainly auxotrophic) amino acids are relaxed and obtained via constrained
 309 optimisation where the SSE is minimised. This strategy ensures that the optimal solution matches
 310 the experimental growth rate and specific productivity while finding the combination of amino
 311 acid uptake fluxes that minimises deviations from the experimental uptake rates.

312 The above strategy yields the results presented in Table 2, where the percent increases in specific
 313 uptake rates required for matching the experimentally determined μ_g and q_p are shown
 314 (positive/red values denote percent increase in uptake fluxes required to match μ_g and q_p). Table
 315 2 shows that for Car LP (NaBu), Selv (Early), Selv (Late), and Mart (Cold2), small or no increases
 316 in amino acid uptake rates are required to match μ_g and q_p . This is expected, considering the
 317 results of Figure 2, where the predicted values for μ_g are matched or exceeded for these datasets.

318 **Table 2. Percent increases in amino acid uptake rates required to match μ_g and q_p . The intensity of**
 319 **the colours (from green = 0% to red) corresponds to magnitudes across all datasets.**

	Car HP	Car HP (NaBu)	Car LP	Car LP (NaBu)	Selv (Early)	Selv (Late)	Mart (Cold1)	Mart (Cold2)	Mart (Warm1)	Mart (Warm2)
μ_g	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_p	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Glc}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Lac}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{NH4}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Pyr}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Ala}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Asn}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Asp}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Gln}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	48.7%	35.0%
q_{Glu}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Gly}	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
q_{Arg}	0.2%	0.0%	8.4%	-0.1%	-0.3%	0.0%	0.8%	-0.4%	17.4%	18.6%
q_{His}	0.5%	25.0%	33.9%	0.0%	0.0%	2.6%	1.8%	0.0%	22.7%	6.8%
q_{Ile}	0.9%	0.0%	20.2%	0.0%	0.0%	0.0%	2.5%	0.0%	9.5%	13.2%
q_{Leu}	13.0%	1.4%	29.8%	0.0%	0.4%	9.0%	5.7%	0.1%	18.6%	16.2%
q_{Lys}	24.7%	0.1%	38.8%	0.0%	0.0%	4.0%	22.0%	0.0%	41.0%	18.7%
q_{Met}	9.4%	0.0%	23.4%	0.0%	0.0%	0.0%	0.0%	0.0%	13.8%	0.1%
q_{Phe}	25.4%	0.0%	47.4%	3.3%	8.4%	10.1%	16.4%	0.1%	33.2%	8.1%
q_{Pro}	0.9%	0.0%	21.9%	0.0%	0.0%	0.0%	2.0%	0.0%	2.4%	7.3%
q_{Ser}	3.3%	0.1%	41.1%	0.1%	0.0%	0.0%	9.1%	0.2%	25.0%	33.4%
q_{Thr}	3.8%	0.0%	15.0%	0.0%	0.5%	0.0%	13.9%	5.3%	9.4%	13.2%
q_{Trp}	0.2%	0.0%	6.2%	0.0%	0.0%	0.0%	0.5%	0.0%	20.0%	2.2%
q_{Tyr}	21.8%	0.0%	41.7%	2.6%	0.0%	0.0%	5.5%	0.1%	28.3%	5.3%
q_{Val}	12.5%	5.1%	34.1%	0.0%	0.6%	6.8%	3.6%	0.0%	17.1%	14.2%

320 Across all other datasets, substantial increases in amino acid uptake rates are required to match
321 the experimental values for μ_g and q_p . Except for both Martínez et al. (2015) Warm datasets, the
322 uptake rate for amino acids which limit growth are auxotrophic (outlined in the bottom half of
323 Table 2) and, in all but one case (Car HP NaBu), multiple auxotrophic amino acids limit the growth
324 rate predictions. Particularly sharp deviations across multiple amino acids are observed for the
325 Car LP and both Mart Warm datasets. In addition, both Mart Warm datasets are the only ones that
326 require increased uptake of Gln.

327 Interestingly, when the upper bound for the Gln uptake flux is completely relaxed for the Mart
328 Warm 2 dataset, a 74.5% increase in uptake for this nutrient is obtained, and only Lys (required
329 14.2% increase) and Thr (required 6.7% increase) are observed to limit growth (data not shown).
330 This result indicates that, for this dataset, the uptake rates of the remaining amino acids do not
331 stoichiometrically limit biomass synthesis. Rather, the limitation in growth is associated with the
332 relatively low uptake rate of Ser which, according to our model, can be overcome by Glu-
333 associated biosynthesis via F_{55} . It is this additional intracellular Glu demand which pushes the
334 uptake rates for Gln, Ile, Leu, Lys, and Val to higher values (Glu can be produced from these amino
335 acids via reactions F_{32} , F_{44} , F_{45} , F_{39} , and F_{41} , respectively).

336 Full relaxation of the Gln uptake upper bound leads to a 65.9% increase and completely curbs the
337 excess requirements for Ser. However, the excess demand for all remaining auxotrophic amino
338 acids (His, Ile, Leu, Lys, Met, Phe, Trp, Tyr, and Val) is unchanged, indicating that for the Mart Cold
339 1 dataset, the uptake rates of auxotrophic amino acids stoichiometrically limit growth.

340 It is key to mention that underestimations for μ_g arise from two possible sources (or a
341 combination thereof): (i) either the assumed stoichiometric coefficients for auxotrophic amino
342 acids in biomass are too high or (ii) the measured uptake rates for auxotrophic amino acids is
343 underestimated. Beyond typical experimental variability, the measured uptake rates are unlikely
344 to have such drastic effects on the predicted growth (errors in uptake rate measurements above
345 30% are unlikely – see Table 2). Therefore, uncertainty associated with biomass composition is

346 the more likely culprit, especially when considering that it has seldom been measured for flux
347 balance studies.

348 Questions surrounding CHO cell biomass composition have been recently addressed, where an
349 average protein content (w/w) of $55.7\% \pm 5.5\%$ and a dry cell weight (DCW) of 262.1 ± 28.2
350 pg/cell is reported for multiple CHO cell lines cultured under different conditions (Szelióva et al.,
351 2020). When comparing these values with the 350pg/cell and 74.2% w/w protein assumed (not
352 measured) for the datasets with the largest shortfalls in predicted μ_g (Martinez Warm), a

353 maximum reduction of $\left(\frac{55.7\% - 5.5\%}{74.2\%}\right) \left(\frac{262.1 \frac{pg}{cell} - 28.2 \frac{pg}{cell}}{350 \frac{pg}{cell}}\right) = 45.3\%$ in amino acid demand towards

354 biomass synthesis can be computed. Such a reduction would compensate for the calculated
355 shortfalls in auxotrophic amino acid uptake rates presented in Table 2 and, therefore, enhance
356 the predictive capability of both our model and Hefzi's GeM.

357 Although detailed data for CHO cell biomass composition is now available (Szelióva et al., 2020),
358 the values of 350pg/cell and 74.2% w/w protein were used for the results presented in Figure 2
359 and Table 2 in order to pinpoint how model predictive capability is impacted by our reduced
360 reaction network when compared with the full GeM. In addition, Supplementary Figure 4
361 provides a comparison between the stoichiometric coefficients of amino acids in biomass
362 assumed here with the experimentally determined ones from Szelióva et al. (2020). Despite
363 considerable differences in DCW (219 pg/cell for exponential growth vs. 262.1 ± 28.2 pg/cell)
364 and protein content (74.2% vs. $55.7\% \pm 5.5\%$), the stoichiometric coefficients result in quite
365 comparable values. Therefore, we have elected to retain our originally assumed biomass
366 composition for all subsequent calculations presented herein.

367 The above results highlight the importance of using accurate measurements for DCW and
368 biomass composition in flux balance modelling. However, it is also important to mention that that
369 biomass composition will impact model predictive capabilities only when auxotrophic
370 components of biomass and product stoichiometrically limit growth and will be less of a factor

371 when nutrient uptake rates exceed stoichiometric requirements. The latter case is observed for
372 the Martinez Cold 2 dataset, where both the GeM and our model considerably over-predict μ_g .
373 Several strategies have been developed to address situations where cell growth is not limited by
374 stoichiometry. On one hand, exploring different metabolic objectives, such as maximising
375 energetic efficiency, minimising redox stress or the uptake of essential nutrients (Chen et al.,
376 2019; Feist and Palsson, 2010; Schuetz et al., 2007) can improve the predictive capability of flux
377 models where nutrient uptake rates stoichiometrically exceed demand for growth and product
378 synthesis. On another hand, strategies to further constrain the allowable values of fluxes through
379 the reaction network have also been explored. For example, Lularevic et al. (2019) provide
380 additional constraints using carbon balancing and Yeo et al. (2020) have developed an interesting
381 framework whereby the fluxes through the reaction network are constrained based on the
382 maximum rates and expression levels of the corresponding metabolic enzymes.

383 **3.2. CHOmpact facilitates easier interpretation of flux distributions.**

384 Our reduced reaction network and multi-objective optimisation strategy has two key advantages
385 over full genome-scale models and the traditional growth rate maximisation objective function
386 used to solve them. Firstly, our multi-objective optimisation strategy enables us to calculate flux
387 distributions across different growth phases (beyond exponential growth) and, therefore,
388 provides enhanced insight into flux distribution dynamics. In addition, the use of multiple
389 objectives further constrains the solution space to achieve flux distributions that are biologically
390 consistent. Secondly, our reduced reaction network simplifies model output interpretation and
391 allows us to better relate the obtained flux distributions with cellular physiology.

392 **3.2.1. Flux distribution dynamics**

393 Figure 3 presents central carbon metabolism and Asp-Mal shuttle fluxes obtained with our
394 reduced reaction network and multi-objective optimisation framework, where the flux maps
395 correspond to three different feed compositions (Feed C, Feed U, and Feed U40) across the five
396 phases of culture identified Supplementary Figure 2.




Figure 3. Flux map comparison

The flux distributions for central carbon metabolism and the aspartate/malate shuttle are shown for five culture intervals (early, mid, and late exponential as well as early and late stationary) across three feed compositions (Feed C, U, and U40). The line thickness corresponds to flux magnitude, as indicated by the legend at the top left-hand corner of each box.

397
398
399
400
401

402 For all feed compositions, the glycolytic fluxes decrease with time, with the highest fluxes
403 observed during early exponential growth and the lowest during stationary growth. The
404 magnitude of the glycolytic flux is largely determined by the glucose uptake rates, which are
405 shown to steadily decrease as culture progresses (Supplementary Figure 2). Conversely, the
406 tricarboxylic acid (TCA) pathway fluxes increase with culture time, which occurs because reduced
407 lactate production allows for more glycolysis-derived pyruvate to reach mitochondria. This
408 phenomenon, often referred to as the Warburg effect, has been widely reported for rapidly
409 proliferating cells, including CHO cells (Buchsteiner et al., 2018; Kelly et al., 2018).

410 The calculated fluxes through the Asp-Mal shuttle are defined by our imposed constraint on F_{20}
411 (Table 1), which limits its value to the flux of 'free' Glu (i.e., the sum of fluxes where this amino
412 acid is produced which are not involved in the Asp-Mal shuttle). This constraint was set because
413 all fluxes along the Asp-Mal shuttle cancel out and, therefore, can have any magnitude if the
414 transfer of reducing equivalents from cytosolic to mitochondrial NADH is balanced. If left
415 unconstrained, Asp-Mal shuttle fluxes have been reported to reach values that are comparable to
416 those through central carbon metabolism (Mulukutla et al., 2012; Nolan and Lee, 2011). Although
417 mathematically correct, these excessive flux values would be limited by the intracellular
418 availability of Glu, which is the key substrate for the rate-limiting Asp-Mal shuttle flux (F_{20})
419 (LaNoue et al., 1974; LaNoue and Tischler, 1974). Despite not directly representing Glu
420 availability, our proposed constraint does limit the upper values of Asp-Mal shuttle fluxes to ones
421 that fall well below those of glycolysis and, therefore, make them more biologically consistent.

422 **3.2.2. Glutamate anaplerosis and cataplerosis**

423 Glutamate can either be consumed towards TCA and energy production (anaplerosis) or
424 produced from TCA metabolites for subsequent use in biomass generation (cataplerosis).
425 According to our reaction network, net Glu anaplerosis occurs when more of this amino acid is
426 transported into mitochondria (F_{20}) than what is transported out, in the form of α KG. Net Glu

427 cataplerosis occurs when less of it is transported into mitochondria than the α KG transported out.
428 α KG is then converted into Glu by either F_{30} or F_{31} , the latter of which uses Asp as a co-substrate.
429 Figure 4 shows that, in Feed C, net Glu cataplerosis (Glu produced from TCA) is observed during
430 the three exponential growth intervals. This trend is reversed during stationary phase, where net
431 anaplerosis (Glu consumed towards TCA) occurs. Feed U and Feed U40 contrast with Feed C in
432 that they present Glu anaplerosis (consumption towards TCA) across all but one culture interval
433 (Figure 4 – bottom).

434 In Feed U, Glu cataplerosis is only observed during mid exponential growth, where its production
435 from TCA accounts for 42.4% of the total Glu inlet (Figure 4 – top). Another interesting feature
436 from Feed U is the level of anaplerosis observed during the early stationary interval, where it
437 accounts for 93.3% of the total consumed Glu (Figure 4 – bottom). This high level of anaplerosis
438 is associated with increased Glu production from Gln (37.3% of total) and, to a lesser extent, from
439 His (18.5% of total) (Figure 4 – top). It is worth noting that this is the only culture condition and
440 interval where Gln is consumed from the extracellular environment (Supplementary Figure 1).

441 In Feed U40, Glu cataplerosis is observed only during the early stationary interval, where 21.4%
442 of all Glu produced is derived from TCA (Figure 4 – top). Glu cataplerosis during early stationary
443 phase is most likely to arise to offset the high level of Gln secretion observed during this interval
444 (Supplementary Figure 1).

445 In our GS-CHO Feed C cultures, Glu cataplerosis is driven by the high Asn uptake rates observed
446 during exponential growth (Supplementary Figure 2), where a high F_{31} flux provides a path for
447 Asn overflow towards pyruvate via oxaloacetate (F_{29}). An alternative cataplerotic pathway for
448 Glu is its direct synthesis from cytosolic α KG via F_{30} (catalysed by enzyme [EC 1.4.1.3](#)), which
449 consumes NH_4^+ and produces cytosolic NAD^+ (Yang et al., 2005) and may, thereby, reduce lactate
450 production (Freund and Croughan, 2018). Its ability to reduce NH_4^+ and lactate production make
451 [EC 1.4.1.3](#) a potential target for metabolic engineering.




Figure 4. Glutamate flux distributions

452

453

454 **The glutamate inlets for all feed compositions are shown in the top half and the outlets are shown**
 455 **in the bottom half. Glutamate sources and sinks are indicated by the shading and the top and bottom**
 456 **legends. The percent contributions to the total inlet or outlet are shown within the bars.**

457 Prior flux balance work on standard (non-GS) CHO cells commonly reports net Glu anaplerosis
 458 during the exponential growth phase of cells, where high lactate production results in low TCA
 459 fluxes (Ahn and Antoniewicz, 2013). It is thought that Glu anaplerosis is used by the cells to
 460 replenish flux through TCA and is also known to be a major source of ammonia production
 461 because much of the anaplerotic flux involves glutamine aminolysis (Dean and Reddy, 2013;
 462 Wahrheit et al., 2014).

463 In contrast to past work, our FBA results indicate substantial Glu anaplerosis during the
 464 stationary phases of culture across all three feeding strategies (Figure 4 – bottom). Our results
 465 suggest that the high uptake rate of Asn observed across all cultures throttles Glu anaplerosis.
 466 The Asn overflow pathway discussed above produces Glu in F₃₁, which, in turn causes Glu
 467 overflow that is taken up by TCA. Anaplerosis as a means to cope with Glu overflow is also
 468 substantiated by the early stationary phase flux distribution of Feed U, which presents the highest
 469 level of Glu anaplerosis observed across all datasets (9.88 nmol/10⁶cells/h) (Figure 4 – bottom).
 470 This culture interval is the only one across all datasets where glutamine (Gln) is consumed by the
 471 cells. It is this Gln uptake which causes Glu overflow through the glutaminolysis pathway that is
 472 commonly reported for non-GS-CHO cells.

473 Glu anaplerosis is commonly described as the cytosolic production of α KG from Glu (via F_{30} –
474 Figure 1), the former of which is transported into the mitochondrial matrix (F_{21}) for uptake by
475 TCA (Ahn and Antoniewicz, 2013; Mulukutla et al., 2012; Nicolae et al., 2014). Crucially, the
476 transport of α KG into the mitochondrial matrix depends on malate availability in the cytosol: F_{21}
477 (OGCP) has an antiport mechanism whereby one molecule of α KG is transported into the
478 mitochondrial lumen for every malate molecule that is transported out (Iacobazzi et al., 1992).


479 Our results indicate an alternative mechanism for Glu anaplerosis, where Glu is first transported
480 into the mitochondrial matrix (via F_{20} – the rate-limiting and only irreversible reaction of the Asp-
481 Mal shuttle (LaNoue et al., 1974; LaNoue and Tischler, 1974)) where it is then converted, with the
482 consumption of mitochondrial Asp, into α KG via F_{22} . This alternative mechanism arises from the
483 high Asn uptake by our GS-CHO cells, where a substantial amount of this nutrient is funnelled
484 towards cytosolic malate through reactions F_{51} , F_{31} , and F_{24} . This Asn overflow pushes α KG out
485 of the mitochondrial matrix where it can be consumed to produce Glu, mainly through F_{31} .
486 Irrespective of the metabolic route, the magnitudes of Glu anaplerosis and cataplerosis are
487 consistent with those determined through Metabolic Flux Analysis (Ahn and Antoniewicz, 2013;
488 Nicolae et al., 2014).

489 **3.2.3. Asparagine and aspartate are key anaplerotic nutrients**

490 The asparagine/aspartate pair (Asn/Asp), linked through F_{51} , is a key contributor to TCA flux
491 through its sequential conversion to oxaloacetate (F_{31}) and pyruvate (F_{29}), the latter of which is
492 ultimately transported into mitochondria for consumption in the TCA. Because alanine and
493 lactate are also produced from pyruvate (through reactions F_{26} and F_{25} , respectively), the
494 Asn/Asp pair is also a key source of these metabolites.

495 During the early exponential interval, cells cultured with Feed C consume 43.9% of Asn/Asp
496 towards TCA and 34.1% towards lactate (Figure 5 – bottom). As lactate secretion subsides, the
497 contribution of Asn/Asp towards TCA increases to beyond 70% for the remaining culture

498 intervals. The trend for Asn/Asp consumption towards TCA is even more pronounced for cells
 499 cultured with Feeds U and U40, where it exceeds 85% across the final three culture intervals.



500

501

Figure 5. Asparagine + Aspartate flux distributions

502 **The sources for asparagine (Asn) and aspartate (Asp) for all feed compositions is shown in the top**
 503 **half and the sinks are shown in the bottom half. The source and sink fluxes for Asn and Asp have**
 504 **been summed for simplicity. The different Asn+Asp sources and sinks are indicated by the shading**
 505 **and the top and bottom legends. The percent contributions to the total sources and sinks are shown**
 506 **within the bars.**

507 Across all feeds, the maximum proportion of Asn/Asp consumed towards biomass and mAb
 508 product is 27.8% for Feed U40 during early exponential phase (Figure 5 – bottom). These results
 509 show that Asn/Asp are fed well beyond stoichiometric requirements for growth and product
 510 formation and that anaplerosis provides an overflow pathway for when these nutrients are fed in
 511 excess. These results are consistent with prior work where excess Asn/Asp feeding has been
 512 observed to increase alanine and lactate secretion by CHO cells (Calmels et al., 2019; Selvarasu et
 513 al., 2012).

514 The anaplerotic overflow pathway for Asn/Asp results in a rapid uptake of Asn and a concomitant
 515 reduction in its concentration in the culture medium (Supplementary Figure 1). Particularly low
 516 residual Asn concentrations are observed in the Feed C culture, where Asn and Asp are fed at the
 517 lowest levels. In absence of flux balance calculations, the observed reduction in Asn availability

518 could be interpreted as being growth limiting and would lead to increasing the concentration of
519 Asn in the media and/or feed to alleviate the perceived bottleneck. Our experimental and FBA
520 results demonstrate that Asn is indeed not a growth limiting nutrient, and that increasing its
521 concentration in the feed in fact reduces cell growth (Supplementary Figure 1), likely due to the
522 production of ammonia associated with Asn anaplerosis. Similar observations were recently
523 reported by Calmels et al. (2019), where GeM FBA calculations were applied to industrial CHO
524 DG44 cells.

525 FBA also allows us to estimate the Asn/Asp uptake rates at which the anaplerotic pathway
526 becomes saturated (i.e., where no more Asn/Asp can be funnelled towards TCA). The raw
527 experimental data shows that Asp accumulates in the extracellular environment of Feed U40
528 cultures during the late exponential, early stationary, and stationary phases (Supplementary
529 Figure 1) implying that, under these conditions, the cells resort to secreting Asp instead of
530 consuming it towards central carbon metabolism. The flux of Asn/Asp towards TCA during these
531 culture phases are 38.7 nmol/10⁶cells/h, 25.7 nmol/10⁶cells/h, and 32.1 nmol/10⁶cells/h,
532 respectively and represent the range of Asn/Asp overflow our GS-CHO cells can cope with.
533 Interestingly, these values closely correlate with the values of total available Glu flux, which are
534 7.3 nmol/10⁶cells/h, 5.5 nmol/10⁶cells/h, and 6.6 nmol/10⁶cells/h for the corresponding culture
535 intervals. This correlation indicates that intracellular Glu availability may regulate the extent of
536 Asn/Asp anaplerosis.

537 **3.2.4. NH₄⁺ sources and sinks**

538 NH₄⁺ is a key determinant of CHO cell culture performance because it is known to impact cell
539 growth (Synoground et al., 2021; Wahrheit et al., 2014) as well as product quality (Borys et al.,
540 1994; Hong et al., 2010). In standard CHO cells, NH₄⁺ is mainly generated as a by-product of Gln
541 anaplerosis (glutaminolysis) (Dean and Reddy, 2013; Hong et al., 2010; Wahrheit et al., 2014).
542 Glutamine synthase (GS) cells, such as the ones used in this study, satisfy their Gln requirements
543 by producing it from Glu via ectopic expression of glutamine synthase, thus circumventing the


544 negative impact of NH_4^+ on the cell culture process. Despite considerable reductions in NH_4^+
545 accumulation, GS-CHO cells still produce ammonia to levels that may still impact product
546 glycosylation (Borys et al., 1994; Hong et al., 2010) so it is therefore important to characterise the
547 major sources and sinks of this key metabolite.

548 The dark blue bars in the top half of Figure 6 show that the vast majority (>75%) of ammonia is
549 produced from asparagine (F_{51}). The only exceptions are the Early Stationary intervals of Feed C
550 and Feed U where, respectively, Asn is the source of 46.4% and 67.5% of all produced NH_4^+ .
551 During the Early Stationary phase of Feed C, the lower levels of NH_4^+ production from Asn are due
552 to depletion of this nutrient in the culture media along with NH_4^+ uptake by the cells
553 (Supplementary Figure 1). In Feed U, the lower proportion of NH_4^+ generated from Asn is caused
554 by glutaminolysis – this is the only interval across all experiments where Gln is consumed by the
555 cells (Supplementary Figure 1). Additional sources of NH_4^+ include Ser (F_{36}), Thr (F_{37}) and His
556 (F_{54}), although to much lower levels, when compared with Asn. These results indicate that, in GS-
557 CHO cells, NH_4^+ production is throttled by the Asn/Asp anaplerosis discussed in section 3.2.3 and
558 is consistent with previous work with GS-CHO cells (Calmels et al., 2019; Carinhas et al., 2013).

559 The total production rate of NH_4^+ further confirms its link with Asn/Asp anaplerosis. The top half
560 of Figure 6 shows that the total amount of NH_4^+ produced by the cells increases with higher levels
561 of Asn feeding. After the Mid Exponential interval, cells cultured with basal Asn feeding levels
562 (Feed C) have NH_4^+ production rates below 8 nmol/ 10^6 cells/h, whereas the Feed U and Feed U40
563 cultures (increasingly higher levels of Asn feeding) produce above 20 nmol/ 10^6 cells/h of NH_4^+ .

564 The bottom half of Figure 6 presents the major NH_4^+ sinks across the three feed conditions, as
565 obtained through our FBA framework. There, it can be seen that three NH_4^+ sinks predominate:
566 (i) secretion to the extracellular (EC) environment (dark blue bars – F_{108}), (ii) consumption in
567 mitochondria (intermediate blue bars) and (iii) consumption towards Gln synthesis (light blue
568 bars – F_{32}). Of the three major sinks, EC secretion can be deduced from the experimental data. The
569 sink towards Gln synthesis is similarly intuitive and occurs because our GS-CHO cells are not fed

570 Gln and must cover their demand for this amino acid through its GS-enabled synthesis using Glu
 571 and NH_4^+ as substrates.



572 **Figure 6. NH_4^+ Flux distributions**

573
 574 **The NH_4^+ sources for all feed compositions are shown in the top half and the sinks are shown in the**
 575 **bottom half. The different sources and sinks are indicated by the shading and the top and bottom**
 576 **legends. The percent contribution of each source/sink to the total produced/consumed is shown**
 577 **within the bars.**

578 The less intuitive NH_4^+ sink is the one associated with mitochondria. According to our FBA results,
 579 a substantial amount of NH_4^+ is consumed by a mitochondrial reaction cycle, where OAA is
 580 combined with Glu to produce αKG and Asp (F_{22}) and where the resulting αKG is combined with
 581 NH_4^+ to produce Glu (F_{23}). This mitochondrial NH_4^+ sink is governed by the presence of Asp within
 582 the mitochondrial lumen and is therefore coupled with the Asp-Mal shuttle, where F_{20} transports
 583 Asp out of mitochondria. If Asp accumulates within mitochondria, F_{22} and F_{23} will be reversed
 584 and may, thereby, cause net NH_4^+ production by mitochondria. These results are consistent with
 585 experimental findings where high NH_4^+ concentrations increased the cell specific consumption
 586 rates of Asp and Glu (Lao and Toth, 1997).

587 Due to the constraint imposed on F_{20} by our FBA solution strategy (discussed in Section 2.2.2 and
 588 presented in Table 1), a second sink for mitochondrial Asp is required to drive mitochondrial
 589 NH_4^+ consumption. Within our FBA reaction network, this additional sink is given by F_{59} of the

590 urea cycle, where mitochondrial Asp is irreversibly combined with citrulline to produce fumarate
591 and arginine (Supplementary Table 1). Our results indicate that F_{59} consumes over half of the
592 mitochondrial Asp across all culture conditions (Supplementary Figure 5) and is, therefore, a key
593 determinant of mitochondrial consumption of NH_4^+ .

594 The above mitochondrial Asp sink (F_{59}) enables mitochondrial consumption of NH_4^+ that is
595 independent of the Asp-Mal shuttle and, therefore, of cytosolic Glu availability. This Glu-
596 independent NH_4^+ detoxification pathway would require diverting aKG directly from TCA to be
597 consumed in reaction F_{23} . The produced Glu would then react with TCA-derived oxaloacetate to
598 replenish aKG and produce mitochondrial Asp (F_{22}). Finally, mitochondrial Asp would be
599 consumed by F_{59} to yield arginine and fumarate, which could also feed back into TCA.

600 Interestingly, CHO cells are reported to produce only trace amounts of urea (Zamorano et al.,
601 2010), indicating that certain enzymes of the cycle may be inactive. The mitochondrial sink
602 identified by our FBA may be an alternate route of NH_4^+ detoxification (independent of urea
603 secretion) that leverages two of the urea cycle enzymes ([EC 6.3.4.5](#) and [EC 4.3.2.1](#)) which are
604 known to be expressed in CHO cells (Heffner et al., 2020).

605 **4. Concluding remarks**

606 We have presented a reduced reaction network to describe the metabolism of mAb-producing
607 CHO cells. Our reduced metabolic network (144 reactions) performs comparably with the
608 iCHO1766 GeM (>6000 reactions) in predicting the growth rates of different CHO cell lines. Our
609 FBA framework also allowed us to identify the absence of cellular weight and composition
610 measurements as the most likely cause of inaccuracies in predicting the growth rates.

611 We have also presented a comprehensive multi-objective optimisation strategy to solve our
612 metabolic model. Our multi-objective optimisation framework constrains the solution space to
613 yield physiologically consistent flux distributions across all phases of cell culture.

614 When coupled with multi-objective optimisation, our compact reaction network greatly enhances
615 the interpretability of metabolic flux distributions across the different phases of cell culture. In
616 this context, our results provide insights into the mechanisms underlying Glu anaplerosis and its
617 dependence on the uptake rate of Asn/Asp. We have also identified Asn and Asp as the key
618 anaplerotic nutrients of GS-CHO cells and that, in this role, they are an important source of lactate
619 during the early stages of culture.

620 Our results also show that Asn is the predominant source of NH_4^+ across all culture conditions
621 and that the major sink for this key metabolite is consumption within mitochondria. The presence
622 of Asp within mitochondria determines whether this organelle is a source or sink of NH_4^+ : when
623 Asp accumulates, mitochondria can become a net source of NH_4^+ , when Asp is depleted, NH_4^+ is
624 consumed within mitochondria. The Asp-Mal shuttle determines the intracellular flux
625 distributions of Asn, Asp, Gln, Glu and NH_4^+ . Our FBA solution strategy constrains fluxes through
626 the Asp-Mal to not exceed the flux of 'free' Glu entering or produced by the cells in order to obtain
627 physiologically consistent flux distributions for Asn, Asp, Gln, Glu and NH_4^+ .

628 Moving forward, the enhanced understanding of metabolic dynamics afforded by our reduced
629 reaction network and multi-objective optimisation framework can be used to define feeding
630 strategies that optimise cell culture performance. Furthermore, the compact size of our reaction
631 network will also facilitate the creation of hybrid dynamic FBA/culture dynamics models which
632 can be used as digital twins for dynamic optimisation and control of cell culture bioprocesses.

633 **Acknowledgements**

634 CK and IJV gratefully acknowledge funding by BRIC/BBSRC. IJV also acknowledges funding from
635 Science Foundation Ireland (12/RC/2275_P2). This manuscript is dedicated in memory of Aoife
636 Carney, Administrative Officer, School of Chemical & Bioprocess Engineering, University College
637 Dublin.

638 **Conflict of interest statement**

639 The authors declare no conflicts of interest.

640 **References**

- 641 Ahn, W. S., Antoniewicz, M. R., 2013. Parallel labeling experiments with [1,2-(13)C]glucose and
642 [U-(13)C]glutamine provide new insights into CHO cell metabolism. *Metab Eng.* 15, 34-47.
643 <https://doi.org/10.1016/j.ymben.2012.10.001>.
- 644 Albrecht, S., Lane, J. A., Marino, K., Al Busadah, K. A., Carrington, S. D., Hickey, R. M., Rudd, P. M.,
645 2014. A comparative study of free oligosaccharides in the milk of domestic animals. *Br J*
646 *Nutr.* 111, 1313-28. <https://doi.org/10.1017/S0007114513003772>.
- 647 Banga, J. R., 2008. Optimization in computational systems biology. *BMC Syst Biol.* 2, 47.
648 <https://doi.org/10.1186/1752-0509-2-47>.
- 649 Baycin-Hizal, D., Tabb, D. L., Chaerkady, R., Chen, L., Lewis, N. E., Nagarajan, H., Sarkaria, V., Kumar,
650 A., Wolozny, D., Colao, J., Jacobson, E., Tian, Y., O'Meally, R. N., Krag, S. S., Cole, R. N., Palsson,
651 B. O., Zhang, H., Betenbaugh, M., 2012. Proteomic analysis of Chinese hamster ovary cells. *J*
652 *Proteome Res.* 11, 5265-76. <https://doi.org/10.1021/pr300476w>.
- 653 Borys, M. C., Linzer, D. I., Papoutsakis, E. T., 1994. Ammonia affects the glycosylation patterns of
654 recombinant mouse placental lactogen-I by chinese hamster ovary cells in a pH-dependent
655 manner. *Biotechnol Bioeng.* 43, 505-14. <https://doi.org/10.1002/bit.260430611>.
- 656 Brady, R. L., Hubbard, R. E., King, D. J., Low, D. C., Roberts, S. M., Todd, R. J., 1991. Crystallization
657 and preliminary X-ray diffraction study of a chimaeric Fab' fragment of antibody binding
658 tumour cells. *J Mol Biol.* 219, 603-4.
- 659 Buchsteiner, M., Quek, L. E., Gray, P., Nielsen, L. K., 2018. Improving culture performance and
660 antibody production in CHO cell culture processes by reducing the Warburg effect.
661 *Biotechnol Bioeng.* 115, 2315-2327. <https://doi.org/10.1002/bit.26724>.
- 662 Calmels, C., McCann, A., Malphettes, L., Andersen, M. R., 2019. Application of a curated genome-
663 scale metabolic model of CHO DG44 to an industrial fed-batch process. *Metab Eng.* 51, 9-19.
664 <https://doi.org/10.1016/j.ymben.2018.09.009>.

- 665 Campbell, M. P., Royle, L., Radcliffe, C. M., Dwek, R. A., Rudd, P. M., 2008. GlycoBase and autoGU:
666 tools for HPLC-based glycan analysis. *Bioinformatics*. 24, 1214-6.
667 <https://doi.org/10.1093/bioinformatics/btn090>.
- 668 Carinhas, N., Duarte, T. M., Barreiro, L. C., Carrondo, M. J., Alves, P. M., Teixeira, A. P., 2013.
669 Metabolic signatures of GS-CHO cell clones associated with butyrate treatment and culture
670 phase transition. *Biotechnol Bioeng*. 110, 3244-57. <https://doi.org/10.1002/bit.24983>.
- 671 Chen, Y., McConnell, B. O., Gayatri Dhara, V., Mukesh Naik, H., Li, C. T., Antoniewicz, M. R.,
672 Betenbaugh, M. J., 2019. An unconventional uptake rate objective function approach
673 enhances applicability of genome-scale models for mammalian cells. *NPJ Syst Biol Appl*. 5,
674 25. <https://doi.org/10.1038/s41540-019-0103-6>.
- 675 Dean, J., Reddy, P., 2013. Metabolic analysis of antibody producing CHO cells in fed-batch
676 production. *Biotechnol Bioeng*. 110, 1735-47. <https://doi.org/10.1002/bit.24826>.
- 677 del Val, I. J., Fan, Y., Weilguny, D., 2016a. Dynamics of immature mAb glycoform secretion during
678 CHO cell culture: An integrated modelling framework. *Biotechnol J*. 11, 610-23.
679 <https://doi.org/10.1002/biot.201400663>.
- 680 del Val, I. J., Polizzi, K. M., Kontoravdi, C., 2016b. A theoretical estimate for nucleotide sugar
681 demand towards Chinese Hamster Ovary cellular glycosylation. *Sci Rep*. 6, 28547.
682 <https://doi.org/10.1038/srep28547>.
- 683 Fan, Y., del Val, I. J., Muller, C., Lund, A. M., Sen, J. W., Rasmussen, S. K., Kontoravdi, C., Baycin-Hizal,
684 D., Betenbaugh, M. J., Weilguny, D., Andersen, M. R., 2015. A multi-pronged investigation into
685 the effect of glucose starvation and culture duration on fed-batch CHO cell culture.
686 *Biotechnol Bioeng*. 112, 2172-84. <https://doi.org/10.1002/bit.25620>.
- 687 Feist, A. M., Palsson, B. O., 2010. The biomass objective function. *Curr Opin Microbiol*. 13, 344-9.
688 <https://doi.org/10.1016/j.mib.2010.03.003>.
- 689 Fouladiha, H., Marashi, S. A., Li, S., Li, Z., Masson, H. O., Vaziri, B., Lewis, N. E., 2021. Systematically
690 gap-filling the genome-scale metabolic model of CHO cells. *Biotechnol Lett*. 43, 73-87.
691 <https://doi.org/10.1007/s10529-020-03021-w>.

- 692 Freund, N. W., Croughan, M. S., 2018. A Simple Method to Reduce both Lactic Acid and Ammonium
693 Production in Industrial Animal Cell Culture. *Int J Mol Sci.* 19.
694 <https://doi.org/10.3390/ijms19020385>.
- 695 Gardner, J. J., Boyle, N. R., 2017. The use of genome-scale metabolic network reconstruction to
696 predict fluxes and equilibrium composition of N-fixing versus C-fixing cells in a diazotrophic
697 cyanobacterium, *Trichodesmium erythraeum*. *BMC Syst Biol.* 11, 4.
698 <https://doi.org/10.1186/s12918-016-0383-z>.
- 699 Gutierrez, J. M., Feizi, A., Li, S., Kallehauge, T. B., Hefzi, H., Grav, L. M., Ley, D., Baycin Hizal, D.,
700 Betenbaugh, M. J., Voldborg, B., Fastrup Kildegaard, H., Min Lee, G., Palsson, B. O., Nielsen,
701 J., Lewis, N. E., 2020. Genome-scale reconstructions of the mammalian secretory pathway
702 predict metabolic costs and limitations of protein secretion. *Nat Commun.* 11, 68.
703 <https://doi.org/10.1038/s41467-019-13867-y>.
- 704 Heffner, K., Hizal, D. B., Majewska, N. I., Kumar, S., Dhara, V. G., Zhu, J., Bowen, M., Hatton, D.,
705 Yerganian, G., Yerganian, A., O'Meally, R., Cole, R., Betenbaugh, M., 2020. Expanded Chinese
706 hamster organ and cell line proteomics profiling reveals tissue-specific functionalities. *Sci*
707 *Rep.* 10, 15841. <https://doi.org/10.1038/s41598-020-72959-8>.
- 708 Hefzi, H., Ang, K. S., Hanscho, M., Bordbar, A., Ruckerbauer, D., Lakshmanan, M., Orellana, C. A.,
709 Baycin-Hizal, D., Huang, Y., Ley, D., Martinez, V. S., Kyriakopoulos, S., Jimenez, N. E., Zielinski,
710 D. C., Quek, L. E., Wulff, T., Arnsdorf, J., Li, S., Lee, J. S., Paglia, G., Loira, N., Spahn, P. N.,
711 Pedersen, L. E., Gutierrez, J. M., King, Z. A., Lund, A. M., Nagarajan, H., Thomas, A., Abdel-
712 Haleem, A. M., Zanghellini, J., Kildegaard, H. F., Voldborg, B. G., Gerdtzen, Z. P., Betenbaugh,
713 M. J., Palsson, B. O., Andersen, M. R., Nielsen, L. K., Borth, N., Lee, D. Y., Lewis, N. E., 2016. A
714 Consensus Genome-scale Reconstruction of Chinese Hamster Ovary Cell Metabolism. *Cell*
715 *Syst.* 3, 434-443 e8. <https://doi.org/10.1016/j.cels.2016.10.020>.
- 716 Heilig, R., Eckenberg, R., Petit, J. L., Fonknechten, N., Da Silva, C., Cattolico, L., Levy, M., Barbe, V.,
717 de Berardinis, V., Ureta-Vidal, A., Pelletier, E., Vico, V., Anthouard, V., Rowen, L., Madan, A.,
718 Qin, S., Sun, H., Du, H., Pepin, K., Artiguenave, F., Robert, C., Cruaud, C., Bruls, T., Jaillon, O.,

719 Friedlander, L., Samson, G., Brottier, P., Cure, S., Segurens, B., Aniere, F., Samain, S., Crespeau,
720 H., Abbasi, N., Aiach, N., Boscus, D., Dickhoff, R., Dors, M., Dubois, I., Friedman, C.,
721 Gouyvenoux, M., James, R., Madan, A., Mairey-Estrada, B., Mangenot, S., Martins, N., Menard,
722 M., Oztas, S., Ratcliffe, A., Shaffer, T., Trask, B., Vacherie, B., Bellemere, C., Belser, C., Besnard-
723 Gonnet, M., Bartol-Mavel, D., Boutard, M., Briez-Silla, S., Combette, S., Dufosse-Laurent, V.,
724 Ferron, C., Lechaplais, C., Louesse, C., Muselet, D., Magdelenat, G., Pateau, E., Petit, E., Sirvain-
725 Trukniewicz, P., Trybou, A., Vega-Czarny, N., Bataille, E., Bluet, E., Bordelais, I., Dubois, M.,
726 Dumont, C., Guerin, T., Haffray, S., Hammadi, R., Muanga, J., Pellouin, V., Robert, D., Wunderle,
727 E., Gauguet, G., Roy, A., Sainte-Marthe, L., Verdier, J., Verdier-Discalca, C., Hillier, L., Fulton, L.,
728 McPherson, J., Matsuda, F., Wilson, R., Scarpelli, C., Gyapay, G., Wincker, P., Saurin, W.,
729 Quetier, F., Waterston, R., Hood, L., Weissenbach, J., 2003. The DNA sequence and analysis of
730 human chromosome 14. *Nature*. 421, 601-7. <https://doi.org/10.1038/nature01348>.
731 Hong, J. K., Cho, S. M., Yoon, S. K., 2010. Substitution of glutamine by glutamate enhances
732 production and galactosylation of recombinant IgG in Chinese hamster ovary cells. *Appl*
733 *Microbiol Biotechnol*. 88, 869-76. <https://doi.org/10.1007/s00253-010-2790-1>.
734 Iacobazzi, V., Palmieri, F., Runswick, M. J., Walker, J. E., 1992. Sequences of the human and bovine
735 genes for the mitochondrial 2-oxoglutarate carrier. *DNA Seq.* 3, 79-88.
736 <https://doi.org/10.3109/10425179209034000>.
737 Jeske, L., Placzek, S., Schomburg, I., Chang, A., Schomburg, D., 2019. BRENDA in 2019: a European
738 ELIXIR core data resource. *Nucleic Acids Res.* 47, D542-D549.
739 <https://doi.org/10.1093/nar/gky1048>.
740 Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., Morishima, K., 2017. KEGG: new perspectives on
741 genomes, pathways, diseases and drugs. *Nucleic Acids Res.* 45, D353-D361.
742 <https://doi.org/10.1093/nar/gkw1092>.
743 Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K., Tanabe, M., 2019. New approach for
744 understanding genome variations in KEGG. *Nucleic Acids Res.* 47, D590-D595.
745 <https://doi.org/10.1093/nar/gky962>.

- 746 Kelly, P. S., Alarcon Miguez, A., Alves, C., Barron, N., 2018. From media to mitochondria–rewiring
747 cellular energy metabolism of Chinese hamster ovary cells for the enhanced production of
748 biopharmaceuticals. *Current Opinion in Chemical Engineering*. 22, 71-80.
749 <https://doi.org/https://doi.org/10.1016/j.coche.2018.08.009>.
- 750 Kol, S., Ley, D., Wulff, T., Decker, M., Arnsdorf, J., Schoffelen, S., Hansen, A. H., Jensen, T. L., Gutierrez,
751 J. M., Chiang, A. W. T., Masson, H. O., Palsson, B. O., Voldborg, B. G., Pedersen, L. E., Kildegaard,
752 H. F., Lee, G. M., Lewis, N. E., 2020. Multiplex secretome engineering enhances recombinant
753 protein production and purity. *Nat Commun*. 11, 1908. [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-020-15866-w)
754 [020-15866-w](https://doi.org/10.1038/s41467-020-15866-w).
- 755 Kremkow, B. G., Baik, J. Y., MacDonald, M. L., Lee, K. H., 2015. CHOgenome.org 2.0: Genome
756 resources and website updates. *Biotechnol J*. 10, 931-8.
757 <https://doi.org/10.1002/biot.201400646>.
- 758 Kremkow, B. G., Lee, K. H., 2018. Glyco-Mapper: A Chinese hamster ovary (CHO) genome-specific
759 glycosylation prediction tool. *Metab Eng*. 47, 134-142.
760 <https://doi.org/10.1016/j.ymben.2018.03.002>.
- 761 Kyriakopoulos, S., Kontoravdi, C., 2014. A framework for the systematic design of fed-batch
762 strategies in mammalian cell culture. *Biotechnol Bioeng*. 111, 2466-76.
763 <https://doi.org/10.1002/bit.25319>.
- 764 LaNoue, K. F., Meijer, A. J., Brouwer, A., 1974. Evidence for electrogenic aspartate transport in rat
765 liver mitochondria. *Arch Biochem Biophys*. 161, 544-50.
- 766 LaNoue, K. F., Tischler, M. E., 1974. Electrogenic characteristics of the mitochondrial glutamate-
767 aspartate antiporter. *J Biol Chem*. 249, 7522-8.
- 768 Lao, M. S., Toth, D., 1997. Effects of ammonium and lactate on growth and metabolism of a
769 recombinant Chinese hamster ovary cell culture. *Biotechnol Prog*. 13, 688-91.
770 <https://doi.org/10.1021/bp9602360>.
- 771 Lewis, N. E., Hixson, K. K., Conrad, T. M., Lerman, J. A., Charusanti, P., Polpitiya, A. D., Adkins, J. N.,
772 Schramm, G., Purvine, S. O., Lopez-Ferrer, D., Weitz, K. K., Eils, R., Konig, R., Smith, R. D.,

- 773 Palsson, B. O., 2010. Omic data from evolved *E. coli* are consistent with computed optimal
774 growth from genome-scale models. *Mol Syst Biol.* 6, 390.
775 <https://doi.org/10.1038/msb.2010.47>.
- 776 Lewis, N. E., Liu, X., Li, Y., Nagarajan, H., Yerganian, G., O'Brien, E., Bordbar, A., Roth, A. M.,
777 Rosenbloom, J., Bian, C., Xie, M., Chen, W., Li, N., Baycin-Hizal, D., Latif, H., Forster, J.,
778 Betenbaugh, M. J., Famili, I., Xu, X., Wang, J., Palsson, B. O., 2013. Genomic landscapes of
779 Chinese hamster ovary cell lines as revealed by the *Cricetulus griseus* draft genome. *Nat*
780 *Biotechnol.* 31, 759-65. <https://doi.org/10.1038/nbt.2624>.
- 781 Lularevic, M., Racher, A. J., Jaques, C., Kiparissides, A., 2019. Improving the accuracy of flux balance
782 analysis through the implementation of carbon availability constraints for intracellular
783 reactions. *Biotechnol Bioeng.* 116, 2339-2352. <https://doi.org/10.1002/bit.27025>.
- 784 Martínez, V. S., Buchsteiner, M., Gray, P., Nielsen, L. K., Quek, L.-E., 2015. Dynamic metabolic flux
785 analysis using B-splines to study the effects of temperature shift on CHO cell metabolism.
786 *Metabolic Engineering Communications.* 2, 46-57.
787 <https://doi.org/https://doi.org/10.1016/j.meteno.2015.06.001>.
- 788 Mulukutla, B. C., Gramer, M., Hu, W. S., 2012. On metabolic shift to lactate consumption in fed-
789 batch culture of mammalian cells. *Metab Eng.* 14, 138-49.
790 <https://doi.org/10.1016/j.ymben.2011.12.006>.
- 791 Nicolae, A., Wahrheit, J., Bahnemann, J., Zeng, A. P., Heinzle, E., 2014. Non-stationary ¹³C metabolic
792 flux analysis of Chinese hamster ovary cells in batch culture using extracellular labeling
793 highlights metabolic reversibility and compartmentation. *BMC Syst Biol.* 8, 50.
794 <https://doi.org/10.1186/1752-0509-8-50>.
- 795 Nolan, R. P., Lee, K., 2011. Dynamic model of CHO cell metabolism. *Metab Eng.* 13, 108-24.
796 <https://doi.org/10.1016/j.ymben.2010.09.003>.
- 797 O'Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., Butler, M., 2020.
798 Mammalian cell culture for production of recombinant proteins: A review of the critical

799 steps in their biomanufacturing. *Biotechnol Adv.* 43, 107552.
800 <https://doi.org/10.1016/j.biotechadv.2020.107552>.

801 O'Leary, N. A., Wright, M. W., Brister, J. R., Ciufu, S., Haddad, D., McVeigh, R., Rajput, B., Robbertse,
802 B., Smith-White, B., Ako-Adjei, D., Astashyn, A., Badretdin, A., Bao, Y., Blinkova, O., Brover, V.,
803 Chetvernin, V., Choi, J., Cox, E., Ermolaeva, O., Farrell, C. M., Goldfarb, T., Gupta, T., Haft, D.,
804 Hatcher, E., Hlavina, W., Joardar, V. S., Kodali, V. K., Li, W., Maglott, D., Masterson, P.,
805 McGarvey, K. M., Murphy, M. R., O'Neill, K., Pujar, S., Rangwala, S. H., Rausch, D., Riddick, L.
806 D., Schoch, C., Shkeda, A., Storz, S. S., Sun, H., Thibaud-Nissen, F., Tolstoy, I., Tully, R. E., Vatsan,
807 A. R., Wallin, C., Webb, D., Wu, W., Landrum, M. J., Kimchi, A., Tatusova, T., DiCuccio, M., Kitts,
808 P., Murphy, T. D., Pruitt, K. D., 2016. Reference sequence (RefSeq) database at NCBI: current
809 status, taxonomic expansion, and functional annotation. *Nucleic Acids Res.* 44, D733-45.
810 <https://doi.org/10.1093/nar/gkv1189>.

811 Orth, J. D., Thiele, I., Palsson, B. O., 2010. What is flux balance analysis? *Nat Biotechnol.* 28, 245-8.
812 <https://doi.org/10.1038/nbt.1614>.

813 Process Systems Enterprise, gPROMS. www.psenterprise.com/gproms. 1997-2020.

814 Rupp, O., MacDonald, M. L., Li, S., Dhiman, H., Polson, S., Griep, S., Heffner, K., Hernandez, I.,
815 Brinkrolf, K., Jadhav, V., Samoudi, M., Hao, H., Kingham, B., Goesmann, A., Betenbaugh, M. J.,
816 Lewis, N. E., Borth, N., Lee, K. H., 2018. A reference genome of the Chinese hamster based on
817 a hybrid assembly strategy. *Biotechnol Bioeng.* 115, 2087-2100.
818 <https://doi.org/10.1002/bit.26722>.

819 Sauer, P. W., Burky, J. E., Wesson, M. C., Sternard, H. D., Qu, L., 2000. A high-yielding, generic fed-
820 batch cell culture process for production of recombinant antibodies. *Biotechnol Bioeng.* 67,
821 585-97.

822 Schuetz, R., Kuepfer, L., Sauer, U., 2007. Systematic evaluation of objective functions for predicting
823 intracellular fluxes in *Escherichia coli*. *Mol Syst Biol.* 3, 119.
824 <https://doi.org/10.1038/msb4100162>.

- 825 Selvarasu, S., Ho, Y. S., Chong, W. P., Wong, N. S., Yusufi, F. N., Lee, Y. Y., Yap, M. G., Lee, D. Y., 2012.
826 Combined in silico modeling and metabolomics analysis to characterize fed-batch CHO cell
827 culture. *Biotechnol Bioeng.* 109, 1415-29. <https://doi.org/10.1002/bit.24445>.
- 828 Sheikh, K., Forster, J., Nielsen, L. K., 2005. Modeling hybridoma cell metabolism using a generic
829 genome-scale metabolic model of *Mus musculus*. *Biotechnol Prog.* 21, 112-21.
830 <https://doi.org/10.1021/bp0498138>.
- 831 Stockmann, H., Adamczyk, B., Hayes, J., Rudd, P. M., 2013. Automated, high-throughput IgG-
832 antibody glycoprofiling platform. *Anal Chem.* 85, 8841-9.
833 <https://doi.org/10.1021/ac402068r>.
- 834 Synoground, B. F., McGraw, C. E., Elliott, K. S., Leuze, C., Roth, J. R., Harcum, S. W., Sandoval, N. R.,
835 2021. Transient ammonia stress on Chinese hamster ovary (CHO) cells yield alterations to
836 alanine metabolism and IgG glycosylation profiles. *Biotechnol J.* 16, e2100098.
837 <https://doi.org/10.1002/biot.202100098>.
- 838 Szeliöva, D., Ruckerbauer, D. E., Galleguillos, S. N., Petersen, L. B., Natter, K., Hanscho, M., Troyer,
839 C., Causon, T., Schoeny, H., Christensen, H. B., Lee, D. Y., Lewis, N. E., Koellensperger, G., Hann,
840 S., Nielsen, L. K., Borth, N., Zanghellini, J., 2020. What CHO is made of: Variations in the
841 biomass composition of Chinese hamster ovary cell lines. *Metab Eng.*
842 <https://doi.org/10.1016/j.ymben.2020.06.002>.
- 843 Wahrheit, J., Nicolae, A., Heinzle, E., 2014. Dynamics of growth and metabolism controlled by
844 glutamine availability in Chinese hamster ovary cells. *Appl Microbiol Biotechnol.* 98, 1771-
845 83. <https://doi.org/10.1007/s00253-013-5452-2>.
- 846 Xiang, J., Prasad, L., Delbaere, L. T., Jia, Z., 1999. Light-chain framework region residue Tyr71 of
847 chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding.
848 *Protein Eng.* 12, 417-21.
- 849 Yang, S. J., Cho, E. H., Choi, M. M., Lee, H. J., Huh, J. W., Choi, S. Y., Cho, S. W., 2005. Critical role of
850 the cysteine 323 residue in the catalytic activity of human glutamate dehydrogenase
851 isozymes. *Mol Cells.* 19, 97-103.

852 Yeo, H. C., Hong, J., Lakshmanan, M., Lee, D. Y., 2020. Enzyme capacity-based genome scale
853 modelling of CHO cells. *Metab Eng.* 60, 138-147.

854 <https://doi.org/10.1016/j.ymben.2020.04.005>.

855 Zamorano, F., Wouwer, A. V., Bastin, G., 2010. A detailed metabolic flux analysis of an
856 underdetermined network of CHO cells. *J Biotechnol.* 150, 497-508.

857 <https://doi.org/10.1016/j.jbiotec.2010.09.944>.

858